source
- Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 programArpeggio Biosciences’ eight-year song has come to an end, as the transcriptome biotech’s CEO admitted the that company’s Nrf2 program had begun to “unravel.”Fierce Biotech · 11h ago↗ source
- BioNTech appoints former Sobi chief Guido Oelkers as new CEOBioNTech has filled its long-vacant chief executive position after a six-month search. The board selected Guido Oelkers, Ph.D., who most recently led Swedish pharmaceutical company Sobi. At Sobi,…
- Novo Nordisk reports mixed trial results for CagriSema and ziltivekimab, cites setbacks and seeks bolt-on deals